This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Atazanavir may slow down how quickly your liver processes amiodarone and lidocaine.
What might happen:
The amount of amiodarone or lidocaine in your blood may increase. This may increase your risk of an irregular heartbeat or other adverse effects.
What you should do about this interaction:
Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of your heart rhythm medicine (antiarrhythmic) in your blood. Your doctor may want to change the dose of your antiarrhythmic. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes, ringing in the ears or tremors.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company September, 2016.
2.Reyataz (atazanavir) Canadian prescribing information. Bristol-Myers Squibb Canada December 3, 2003.
3.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.
4.Reyataz (atazanavir) UK summary of product characteristics. Bristol-Myers Squibb Pharmaceuticals Limited September 8, 2008.
5.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
6.Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004 Jan;75(1):80-8.
7.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..